Clinical Trial Update: A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas [Phase 1]

View source ↗

Summary

A Phase 1 study of CG-806 in relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, and non-Hodgkin's lymphomas has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• CG-806

Snippet

Sponsor: Aptose Biosciences Inc. | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 | Status: TERMINATED